Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CCCC
#2959
C4 Therapeutics, Inc.
2.7
0
-1.46%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-1.46%
Monthly Change
+26.17%
6 month change
+5.06%
Year Change
+4.25%
Previous Close
2.7
4
Open
2.7
0
Bid
Ask
Low
2.7
0
High
2.7
0
Volume
57
Markets
US Stock Market
Healthcare
CCCC
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
70.59 M
70.99 M
71.01 M
71.17 M
96.91 M
97.58 M
—
Valuation ratios
Enterprise value
342.71 M
200.06 M
62.32 M
23.62 M
156.34 M
111.77 M
354.05 M
Price to earnings ratio
-3.35
-2.37
-1.08
-0.9
-1.32
-1.5
-4.81
Price to sales ratio
11.28
7.02
2.8
2.93
5.25
—
—
Price to cash flow ratio
4.88
3.83
1.39
1.15
1.67
1.6
5.82
Price to book ratio
0.36
1.16
0.12
0.12
0.21
0.62
1.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.07
0.1
0.08
0.09
0.12
0.06
0.35
Return on equity %
0.1
0.16
0.13
0.15
0.21
0.08
0.57
Return on invested capital %
76.84
112.39
92.51
98.05
140.69
87
418.25
Gross margin %
100
100
100
100
100
100
400
Operating margin %
183.86
728.39
402.93
440.99
306.43
210.1
1 360.45
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
160.57
667.82
363.66
402.6
286.43
185.97
1 238.66
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.31
5.71
5.7
5.06
5.76
7.81
24.32
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.02
0.02
0.04
0.04
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.35
0.26
0.47
0.17
0.43
0.27
1.34
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.08
3.85
3.31
3.14
2.75
3.58
12.79
Net current asset value per share
3.92
3.72
3.28
3.16
2.85
3.11
12.41
Tangible book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Working capital per share
3.3
3.06
2.71
2.54
2.36
2.72
10.32
Book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
News
Barclays上调C4 Therapeutics股票目标价,因临床试验取得进展
Barclays raises C4 Therapeutics stock price target on trial progress
TD Cowen重申C4 Therapeutics股票买入评级
TD Cowen reiterates Buy rating on C4 Therapeutics stock
C4Q4每股收益及营收超出预期
C4 earnings beat by $0.11, revenue topped estimates
Brookline Capital上调C4 Therapeutics目标价,看好试验进展
Brookline Capital raises C4 Therapeutics stock price target on trial progress
C4 Therapeutics doses first patient in phase 2 myeloma trial
C4 Therapeutics首席医疗官Reyno出售价值22,200美元的股票
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock
C4 Therapeutics将推进多发性骨髓瘤cemsidomide临床试验